Antimicrobial Resistance (AMR) Action Fund
The Antimicrobial Resistance (AMR) Action Fund was established in July 2020 by more than 20 leading biopharmaceutical companies as a groundbreaking initiative aimed at commercializing and delivering two to four new antimicrobial drugs to patients by 2030.The fund is an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). As an IFPMA member organization, the JPMA contributed to the fund’s establishment and is actively promoting advocacy efforts.
- Antimicrobial Resistance (AMR) Action Fund Website
(August 2021: The Japanese-language website was launched)
Announcement Regarding the Antimicrobial Resistance (AMR) Action Fund
● The AMR Action Fund has announced its first investment.
We are pleased to announce that the AMR Action Fund has announced its first investment.
Please see the original English text of this announcement at https://www.amractionfund.com/resources/amr-action-fund-first-investments.
Please refer to this link for the Japanese translation of this joint statement:
-
*The Japanese translation provided here is based on the press release issued by the AMR Action Fund on April 4, 2022, which has been translated into Japanese and edited for your reference. The official language is English, and the English text shall take precedence regarding the content and interpretation of this document.